GET DAILY SIGNALSImmutep Limited (IMMP) +7% Rebound: Clinical Data and Narrowed Strategy in Focus
Key Takeaways
- Immutep Limited (IMMP) is a clinical-stage biotechnology company pioneering LAG-3 immunotherapy for cancer and autoimmune diseases, with lead programs eftilagimod alfa ("efti") and IMP761.
- Over the last 30 days, IMMP's net move was modest at roughly +7%, but the period was marked by pronounced volatility, including a slide through October and a double-digit rebound in early November.
- The rebound followed positive Phase I data for IMP761 presented at ACR Convergence 2026, alongside a newly outlined, focused development strategy for efti.
- Registration-directed work on efti now centers on head and neck cancer and neoadjuvant soft tissue sarcoma, with the next trial start targeted for the second half of 2027.
- Cost reductions after the TACTI-004 Phase III discontinuation are expected to extend the company's cash runway into the first half of 2028.
- Despite the recent bounce, the stock's longer-term trend remains sharply lower following the March 2026 TACTI-004 futility outcome.
- For additional context on valuation and catalysts, review Immutep's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how automated trading strategies are tracking tickers like IMMP.
Market Snapshot and Recent Price Action
Immutep's American Depositary Receipts trade on the Nasdaq under the ticker IMMP, with the underlying shares listed on the ASX as IMM. As of the latest available session, the ADR traded around $3.90, a net gain of roughly 7% versus the closing level of $3.63 recorded 30 calendar days earlier. That headline figure, however, understates the volatility beneath the surface: the stock drifted lower through most of October, closed near $2.69 in early November, and then surged more than 24% in a single session as fresh clinical and strategic updates reached investors.
The company remains a small-cap, clinical-stage name whose share price is driven primarily by data readouts, regulatory developments, and pipeline execution rather than revenue or earnings. Immutep regained Nasdaq listing compliance in October 2026 after adjusting its ADR ratio, a move that followed an earlier bid-price deficiency notice and reflects the extended pressure the shares have faced over the trailing year. I also checked this using Tickeron’s AI Pattern Search Engine to see how the stock compares to others in the industry.
Business Overview and Competitive Position
Headquartered in Sydney, Australia, Immutep is a clinical-stage immunotherapy company and a recognized pioneer in the biology of Lymphocyte Activation Gene-3 (LAG-3). Its diversified portfolio seeks to harness LAG-3's dual ability to either stimulate or suppress the immune response, spanning both oncology and autoimmune disease.
The lead oncology candidate, eftilagimod alfa (efti), is a soluble LAG-3 protein that activates antigen-presenting cells and is being developed in combination with checkpoint inhibitors and chemotherapy. Its most advanced autoimmune program, IMP761, is a first-in-class LAG-3 agonist antibody designed to dampen the pathogenic T-cell responses that drive diseases such as rheumatoid arthritis. The portfolio also includes the earlier-stage antibody programs ieramilimab (IMP701) and GSK781 (IMP731), the latter partnered with GlaxoSmithKline. In licensed territories, efti is partnered with Dr. Reddy's Laboratories (RDY), while Immutep retains rights in North America, Europe, and Japan.
Immutep's competitive edge rests on more than two decades of LAG-3 expertise and a mechanism-first approach that differentiates efti from anti-PD-1 therapies such as Merck's (MRK) Keytruda. Investors follow the stock for its clinical catalysts across first-line non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and soft tissue sarcoma.
Recent Developments and Catalysts
The sharp early-November rebound was fueled by two closely spaced announcements. First, Immutep reported positive Phase I data for IMP761 from a late-breaking abstract at ACR Convergence 2026, showing statistically significant, exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers. The asset was well tolerated across all seven dose levels, and its pharmacokinetic profile supports a four-week dosing interval, positioning it for the multiple-ascending-dose portion of the study and a potential future Phase II program.
Second, the company outlined a focused development strategy for efti. A root-cause analysis of the TACTI-004 Phase III failure identified manufacturing-scale differences between efti batches, prompting a new 200-liter manufacturing run and a narrowed pipeline focused on HNSCC with low PD-L1 expression and neoadjuvant soft tissue sarcoma. This strategy follows the April 2026 FDA Orphan Drug Designation for efti in soft tissue sarcoma and the EFTISARC-NEO Phase II trial meeting its primary endpoint. Positive mature overall survival data from the INSIGHT-003 study, which reported a median of 30.9 months in first-line NSCLC, continue to support the broader efti mechanism.
These catalysts arrived against a difficult backdrop: the March 2026 discontinuation of TACTI-004 for futility triggered a severe repricing, cost-reduction measures, and a putative U.S. securities class action that was voluntarily dismissed. The company's cash balance of approximately A$48.5 million as of September 30, 2026, combined with leaner spending, is expected to fund operations into the first half of 2028.
2026 Outlook and Key Milestones to Watch
Looking ahead, several milestones are likely to shape IMMP's trajectory. Results from the multiple-ascending-dose portion of the IMP761 Phase I study are anticipated in the first half of 2027 and are expected to inform dose selection for a potential Phase II trial. On the oncology side, the start of the next efti trial is targeted for the second half of 2027, subject to manufacturing validation, regulatory feedback, and partnering considerations.
Investors should also monitor the completion of the efti root-cause analysis and the new 200-liter manufacturing run, which are central to restoring confidence in the program after TACTI-004. Cash runway, financing decisions, and broader competitive dynamics in the LAG-3 and immuno-oncology space remain key risk factors. As a clinical-stage biotech with no approved products, Immutep's share price will likely continue to be driven by discrete data and regulatory events rather than fundamental earnings. One thing that stands out is how these binary events can shift sentiment quickly in this space.
Monitoring with AI Trading Tools
I've found Tickeron's Trending AI Robots page useful for getting a curated view of automated trading strategies across volatile names like this one. It surfaces top-performing bots with different strategies and timeframes, letting me compare momentum signals without relying on a single model. This adds a data-driven layer to tracking catalyst-driven biotech stocks and helps put technical moves in context alongside the clinical news.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IMMP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for IMMP turned positive on October 20, 2026. Looking at past instances where IMMP's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMMP's RSI Indicator exited the oversold zone, 22 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMMP as a result. In 69 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMP advanced for three days, in 211 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IMMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for IMMP entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.999) is normal, around the industry mean (3.498). P/E Ratio (-0.310) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. IMMP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of anti-cancer therapeutics
Industry Biotechnology
Advertisement